BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghosh A, Mailankody S, Giralt SA, Landgren CO, Smith EL, Brentjens RJ. CAR T cell therapy for multiple myeloma: where are we now and where are we headed? Leuk Lymphoma 2018;59:2056-67. [PMID: 29105517 DOI: 10.1080/10428194.2017.1393668] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Giralt S, Seifter E. Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients. Hematology Am Soc Hematol Educ Program 2018;2018:103-9. [PMID: 30504298 DOI: 10.1182/asheducation-2018.1.103] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Tan CR, Shah UA. Targeting BCMA in Multiple Myeloma. Curr Hematol Malig Rep 2021;16:367-83. [PMID: 34432234 DOI: 10.1007/s11899-021-00639-z] [Reference Citation Analysis]
3 Hernández-López A, Téllez-González MA, Mondragón-Terán P, Meneses-Acosta A. Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope. Front Pharmacol 2021;12:720692. [PMID: 34489708 DOI: 10.3389/fphar.2021.720692] [Reference Citation Analysis]
4 Mohammed T, Mailankody S. “Off-the-shelf” immunotherapies for multiple myeloma. Seminars in Oncology 2022. [DOI: 10.1053/j.seminoncol.2022.01.001] [Reference Citation Analysis]
5 Landgren CO, Chari A, Cohen YC, Spencer A, Voorhees P, Estell JA, Sandhu I, Jenner MW, Williams C, Cavo M, van de Donk NWCJ, Beksac M, Moreau P, Goldschmidt H, Kuppens S, Bandekar R, Clemens PL, Neff T, Heuck C, Qi M, Hofmeister CC. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). Leukemia 2020;34:1840-52. [PMID: 32024950 DOI: 10.1038/s41375-020-0718-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
6 Ganatra S, Parikh R, Neilan TG. Cardiotoxicity of Immune Therapy. Cardiol Clin. 2019;37:385-397. [PMID: 31587780 DOI: 10.1016/j.ccl.2019.07.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
7 Bai Z, Shen J, Tang M. Effect of Autologous Stem Cell Transplantation Combined with Modified VTD Regimen on Elderly Patients with Multiple Myeloma and Its Influence on miRNA Cytokines. Computational and Mathematical Methods in Medicine 2022;2022:1-8. [DOI: 10.1155/2022/6320329] [Reference Citation Analysis]
8 Ni B, Hou J. Promising therapeutic approaches for relapsed/refractory multiple myeloma. Hematology 2022;27:343-52. [PMID: 35287555 DOI: 10.1080/16078454.2022.2045724] [Reference Citation Analysis]
9 Aljama MA, Sidiqi MH, Dingli D. Therapy for relapsed multiple myeloma. Panminerva Med 2018;60:174-84. [PMID: 30303355 DOI: 10.23736/S0031-0808.18.03542-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Tschumi BO, Dumauthioz N, Marti B, Zhang L, Lanitis E, Irving M, Schneider P, Mach JP, Coukos G, Romero P, Donda A. CART cells are prone to Fas- and DR5-mediated cell death. J Immunother Cancer 2018;6:71. [PMID: 30005714 DOI: 10.1186/s40425-018-0385-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
11 Teoh PJ, Chng WJ. CAR T-cell therapy in multiple myeloma: more room for improvement. Blood Cancer J 2021;11:84. [PMID: 33927192 DOI: 10.1038/s41408-021-00469-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
12 Berahovich R, Zhou H, Xu S, Wei Y, Guan J, Guan J, Harto H, Fu S, Yang K, Zhu S, Li L, Wu L, Golubovskaya V. CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth. Cancers (Basel) 2018;10:E323. [PMID: 30208593 DOI: 10.3390/cancers10090323] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
13 Ria R, Vacca A. Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma. Int J Mol Sci 2020;21:E613. [PMID: 31963513 DOI: 10.3390/ijms21020613] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
14 Firer MA, Luboshits G. Antibody‐Drug‐Conjugate Therapy for Hematological Cancers: Matching Cell Biology with Clinical Benefit. Adv Funct Mater 2021;31:2100032. [DOI: 10.1002/adfm.202100032] [Reference Citation Analysis]
15 Giralt S, Costa LJ, Maloney D, Krishnan A, Fei M, Antin JH, Brunstein C, Geller N, Goodman S, Hari P, Logan B, Lowsky R, Qazilbash MH, Sahebi F, Somlo G, Rowley S, Vogl DT, Vesole DH, Pasquini M, Stadtmauer E. Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biol Blood Marrow Transplant 2020;26:798-804. [PMID: 31756536 DOI: 10.1016/j.bbmt.2019.11.018] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
16 Caro J, Braunstein M, Williams L, Bruno B, Kaminetzky D, Siegel A, Razzo B, Alfandari S, Morgan GJ, Davies FE, Boyle EM. Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients. Leukemia 2022. [PMID: 35110727 DOI: 10.1038/s41375-021-01506-9] [Reference Citation Analysis]
17 Cherian S, Stetler-Stevenson M. Flow Cytometric Monitoring for Residual Disease in B Lymphoblastic Leukemia Post T Cell Engaging Targeted Therapies. Curr Protoc Cytom 2018;86:e44. [PMID: 30212602 DOI: 10.1002/cpcy.44] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
18 Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, Yuan J, Wang X, Wang Y, Deng Q. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. Front Immunol 2021;12:720571. [PMID: 34421924 DOI: 10.3389/fimmu.2021.720571] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Hill JA, Giralt S, Torgerson TR, Lazarus HM. CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy. Blood Rev 2019;38:100596. [PMID: 31416717 DOI: 10.1016/j.blre.2019.100596] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
20 Ma R, Yu D, Peng Y, Yi H, Wang Y, Cheng T, Shi B, Yang G, Lai W, Wu X, Lu Y, Shi J. Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells. Acta Biochim Biophys Sin (Shanghai) 2021;53:775-83. [PMID: 33891090 DOI: 10.1093/abbs/gmab042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
21 Lesokhin AM, Bal S, Badros AZ. Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma. Cancer Immunol Res 2019;7:1224-9. [PMID: 31371317 DOI: 10.1158/2326-6066.CIR-19-0148] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
22 Lei X, Lei Y, Li JK, Du WX, Li RG, Yang J, Li J, Li F, Tan HB. Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy. Cancer Lett 2020;470:126-33. [PMID: 31730903 DOI: 10.1016/j.canlet.2019.11.009] [Cited by in Crossref: 82] [Cited by in F6Publishing: 101] [Article Influence: 27.3] [Reference Citation Analysis]
23 Golubovskaya V, Zhou H, Li F, Berahovich R, Sun J, Valentine M, Xu S, Harto H, Sienkiewicz J, Huang Y, Wu L. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma. Biomedicines 2021;9:1422. [PMID: 34680541 DOI: 10.3390/biomedicines9101422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Abdou P, Wang Z, Chen Q, Chan A, Zhou DR, Gunadhi V, Gu Z. Advances in engineering local drug delivery systems for cancer immunotherapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2020;12:e1632. [PMID: 32255276 DOI: 10.1002/wnan.1632] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
25 Quazi S. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy. Clin Lymphoma Myeloma Leuk 2022;22:e392-404. [PMID: 34992008 DOI: 10.1016/j.clml.2021.12.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Leleu X, Chari A, Richard S, Khurana M, Yusuf A, Usmani SZ. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. Expert Rev Hematol 2021;:1-10. [PMID: 34546844 DOI: 10.1080/17474086.2021.1955343] [Reference Citation Analysis]
27 Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 2020;34:985-1005. [PMID: 32055000 DOI: 10.1038/s41375-020-0734-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 36.0] [Reference Citation Analysis]
28 Shah UA, Mailankody S. CAR T and CAR NK cells in multiple myeloma: Expanding the targets. Best Pract Res Clin Haematol 2020;33:101141. [PMID: 32139020 DOI: 10.1016/j.beha.2020.101141] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
29 Zhou S, Wang R. Targeted therapy of multiple myeloma. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2021.00057] [Reference Citation Analysis]
30 Feng D, Sun J. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma. Scand J Immunol 2020;92:e12910. [PMID: 32471019 DOI: 10.1111/sji.12910] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Hill JA, Seo SK. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 2020;136:925-35. [PMID: 32582924 DOI: 10.1182/blood.2019004000] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 28.0] [Reference Citation Analysis]
32 Rosenblatt J, Avigan D. Cellular Immunotherapy for Multiple Myeloma. Cancer J 2019;25:38-44. [PMID: 30694858 DOI: 10.1097/PPO.0000000000000356] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
33 Shah UA, Smith EL. Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells. Cancer J 2019;25:208-16. [DOI: 10.1097/ppo.0000000000000379] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
34 Shah UA, Mailankody S. Emerging immunotherapies in multiple myeloma. BMJ 2020;370:m3176. [PMID: 32958461 DOI: 10.1136/bmj.m3176] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
35 Wang X, Borquez-Ojeda O, Stefanski J, Du F, Qu J, Chaudhari J, Thummar K, Zhu M, Shen LB, Hall M, Gautam P, Wang Y, Sénéchal B, Sikder D, Adusumilli PS, Brentjens RJ, Curran K, Geyer MB, Mailankhody S, O'Cearbhaill R, Park JH, Sauter C, Slovin S, Smith EL, Rivière I. Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing. Mol Ther Methods Clin Dev 2021;22:377-87. [PMID: 34514029 DOI: 10.1016/j.omtm.2021.06.014] [Reference Citation Analysis]
36 Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M. Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study. JACC CardioOncol 2020;2:193-203. [PMID: 32776016 DOI: 10.1016/j.jaccao.2020.04.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]